Core Symptom of Schizophrenia Eliminated Friday, February 19, 2016 Team uses chemical compound to restore affected brain regions; findings could lead to new treatment strategies.Structure of ‘Smart’ Nanogels at Air/Water Interface Revealed Friday, February 19, 2016 Findings may lead to better drug administration practices than current methods. Spero Therapeutics Announces $30 Million Series B Preferred Financing Wednesday, February 10, 2016 Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.Synthesis and Kilo Lab Extensions to US facility Tuesday, February 09, 2016 Company builds a new synthesis laboratory and a kilo lab for US facility.Biogen Joins Pioneering Target Validation Collaboration Tuesday, February 09, 2016 The Centre for Therapeutic Target Validation welcomes new member Biogen, expanding its efforts to accelerate drug discovery research.Keeping Tumor Growth at Bay Friday, February 05, 2016 Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.Nordic Nanovector Awarded NOK 15M Friday, February 05, 2016 Nordic Nanovector ASA is pleased to announce the award of a up to NOK 15 million grant from the Research Council of Norway’s User-driven Research-based Innovation programme to support the research and development of novel targeted therapeutics for leukemia and non-Hodgkin Lymphoma. Future of Medicine Could be Found in a Tiny Crystal Ball Thursday, February 04, 2016 A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.DTRA Awards $9.7M Contract for Drug Development Thursday, February 04, 2016 The Defense Threat Reduction Agency (DTRA) has awarded Emory University a $9.7M contract to develop drugs to treat infections caused by emerging and man-made viral threats. Under the contract, the DTRA funds will be used to advance the development of the lead drug candidate.